Tag: costs

Innovative patient-centred lung clinic reduces suffering along with costs

A unique clinic for patients with terminal lung disease is leading to dramatic reductions in hospital deaths, better symptom management and lower costs for the health-care system. The multidisciplinary team at Alberta Health Services’ Kaye Edmonton Interstitial Lung Disease Clinic delivers palliative care and encourages treatment at home for patients with idiopathic pulmonary fibrosis (IPF).

Brazil sues tobacco companies to recover public health costs

Brazil’s Attorney General’s Office is suing multinational tobacco companies to recover costs by the public health care system in treating smoking-related illnesses. The suit, filed against British American Tobacco and Philip Morris International on Tuesday, seeks to recover costs spent treating 26 diseases with scientifically proven links to tobacco usage in the last five years.

Wearable sensor may cut costs and improve access to biofeedback for people with incomplete paraplegia

A new electromyography biofeedback device that is wearable and connects to novel smartphone games may offer people with incomplete paraplegia a more affordable, self-controllable therapy to enhance their recovery, according to a new study presented this week at the Association of Academic Physiatrists Annual Meeting in Puerto Rico. Electromyography (recording electrical activity of muscles) biofeedback

VA MISSION Act May Up Costs, Lower Vet Health Care Quality

TUESDAY, July 24, 2018 — The Veterans Affairs Maintaining Internal Systems and Strengthening Integrated Outside Networks (VA MISSION) Act may increase costs and reduce quality of health care for veterans, according to an Ideas and Opinions piece published online July 24 in the Annals of Internal Medicine. Joel Kupfer, M.D., from the University of Arizona

Germany: compensated cirrhosis substantially increases comorbidities and healthcare costs

An analysis of outcomes and costs for German patients with non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH) who develop compensated cirrhosis was presented today at The International Liver Congress 2018 in Paris, France. Healthcare costs for this population spiked in the first year after compensated cirrhosis diagnosis. Comorbidities were common and one in five patients

Outcomes-based pricing doesn’t cut costs of PCSK9 inhibitors

(HealthDay)—Outcomes-based pricing does not reduce the costs of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, according to a research letter published online April 3 in the Annals of Internal Medicine. Dhruv S. Kazi, M.D., from the University of California in San Francisco, and colleagues examined the effect of outcomes-based pricing on the cost-effectiveness of PCSK9